Two urologic surgeons at Vanderbilt-Ingram Cancer Center are among a leading group of cancer physicians using an innovative new imaging agent and blue light system to “light up” cancerous cells inside the bladder. The combined system is used to confirm non-invasive papillary cancer inside the bladder and help surgeons detect and remove more of the […]
One of the most promising cancer prevention targets to emerge in the 1990s was the enzyme cyclooxygenase-2 (COX-2). Raymond Dubois, M.D., Ph.D., and his lab were the first in the world to report that COX-2 expression is elevated in human colorectal cancers and that inhibitors of the enzyme block the growth of colorectal cancer cells […]
Arteaga to lead American Association for Cancer Research Carlos Arteaga, M.D., professor of Medicine and Cancer Biology at Vanderbilt, has been elected president-elect of the American Association for Cancer Research for 2013-2014. Elected by the organization’s members, Arteaga will work with the AACR board of directors and the 34,000-plus membership to further the AACR’s mission […]
Vanderbilt-Ingram Cancer Center is committed to conducting innovative, high-impact, basic, translational and clinical research with the greatest potential for making a difference for cancer patients, today and in the future. Here’s a sampling of work published in peer-reviewed journals by Cancer Center investigators in 2012-2013: Long-term effects of prostate therapies tracked A new study published […]
Comprehensive Cancer Center is the highest ranking awarded by the National Cancer Institute, one of the National Institutes of Health and the nation’s foremost authority on cancer. NCI-designated cancers centers are institutions dedicated to research in the development of more effective approaches to prevention, diagnosis and treatment of cancer. Of the 67 NCI-designated cancer centers, […]
Population-based studies provide answers to critical questions about the prevention of cancer and other diseases. VICC manages three large population-based prospective cohort studies with more than 225,000 participants. The Southern Community Cohort Study (SCCS), initiated in 2001 and supported by Caterpillar Inc., has enrolled more than 86,000 participants in 12 states. It seeks to answer […]
When Hal Moses, M.D., and his colleagues at the Mayo Clinic first described and purified a “transforming growth factor” in the early 1980s, they had no idea what they were about to unleash. Today, TGF-beta touches every part of cancer biology. The TGF-beta signaling pathway regulates cell growth and proliferation and is altered in several […]
Melanoma, a form of skin cancer, is especially lethal when it metastasizes to other areas of the body. About half of melanomas have a mutation in the BRAF gene, and VICC investigators were instrumental in testing a new drug, which turned out to be a potent inhibitor of a mutated form of BRAF called V600E. […]
In March 2011, VICC launched the nation’s first personalized cancer decision support tool, “My Cancer Genome,” to help physicians and researchers track the latest developments in personalized cancer medicine and connect with clinical research trials for their patients. This Web-based information tool is designed to quickly educate clinicians on the rapidly expanding list of genetic […]
